Arvinas Holding Company (ARVN)
NASDAQ:ARVN
Want to see ARVN full AI Analyst Report?
ARVN Stock Chart & Stats
$11.00
$0.30(1.54%)
At close: 4:00 PM EST
$11.00
$0.30(1.54%)
Day’s Range― - ―
52-Week Range$6.06 - $14.51
Previous CloseN/A
Volume216.17K
Average Volume (3M)860.73K
Market Cap
$587.14M
Enterprise Value$508.44M
Total Cash (Recent Filing)$614.90M
Total Debt (Recent Filing)$8.60M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Jul 30, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.26
Shares Outstanding64,521,194
10 Day Avg. Volume1,091,854
30 Day Avg. Volume860,732
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)1.77
Price to Sales (P/S)2.93
P/FCF Ratio-2.79
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue5.69
Enterprise Value/Gross Profit5.84
Enterprise Value/Ebitda-2.19
Forecast
1Y Price Target
$15.64Price Target Upside42.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)-2.93
Revenue Forecast (FY)$117.79M
Bulls Say, Bears Say
Bulls Say
Clinical Biomarker EfficacyARV-102 produced consistent reductions in cerebrospinal fluid and blood markers tied to LRRK2 activity and neuroinflammation, providing human proof-of-concept for brain target engagement and pathway modulation.
Clinical Development MomentumPhase 1 programs for ARV-806 and ARV-102 enrolled quickly and showed tolerable safety profiles, accelerating clinical data generation that could drive revaluation as programs advance.
Differentiated Mechanism And Pipeline BreadthThe PROTAC degrader approach that removes the entire LRRK2 protein and ARV-806's targeting of both active and inactive KRAS forms create mechanistic differentiation versus kinase inhibitors and broaden potential indications across neurodegeneration and oncology.
Bears Say
Clinical Benefit UncertaintyBiomarker improvements with ARV-102 have not yet been shown to produce meaningful functional benefit in patients, leaving a central efficacy risk for later-stage trials.
Market Size And Competitive PressureIf use of the therapy is restricted to patients with a specific genetic form of disease, the addressable patient population may be small and competing programs in broader populations could limit commercial uptake.
Pulmonary Safety RiskLRRK2-targeted therapies have known associations with lung effects, so longer-duration pulmonary monitoring is required and emerging lung toxicity could impose development hurdles.
Arvinas Holding Company News
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $6.05 and its highest was $14.51 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Arvinas Holding Company’s market cap is $587.14M.
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Jul 30, 2026 which is in 70 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on May 12, 2026. The company reported -$0.9 earnings per share for the quarter, beating the consensus estimate of -$0.924 by $0.024.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -0.4.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 64,521,194 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of -$0.9 in its last earnings report, beating expectations of -$0.924. Following the earnings report the stock price went down -0.932%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Currently, no hedge funds are holding shares in ARVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arvinas Holding Company Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.64 (42.21% Upside)
$15.64 (42.21% Upside)
Hedge Fund Trend
Increased
By 83.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $816.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
37.04%
12-Months-Change
Fundamentals
Return on Equity
-44.39%
Trailing 12-Months
Asset Growth
-35.32%
Trailing 12-Months
Company Description
Arvinas Holding Company
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
ARVN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented several major positive developments — notably the landmark FDA approval of VEPPANU (first heterobifunctional PROTAC approval), a global out-license to Rigel, robust early clinical and compelling preclinical data across multiple programs (ARV-102, ARV-806, ARV-393, ARV-6723, pan-KRAS), a healthy cash runway into H2 2028, and significant non-GAAP expense reductions improving financial flexibility. Counterbalancing these positives were a steep year-over-year revenue decline (driven by collaborative accounting changes), a quarter-over-quarter cash decline, an FDA-requested hold on the U.S. ARV-102 Phase 1b pending chronic NHP tox data (delaying U.S. patient dosing), and competitive/safety uncertainties in the KRAS landscape. Overall, the highlights — including the validation of the platform, key partnerships, and multiple programs advancing — materially outweigh the lowlights, supporting a positive outlook for the company.View all ARVN earnings summariesARVN Stock 12 Month Forecast
Average Price Target
$15.64
▲(42.21% Upside)
Technical Analysis
AnaptysBio
―
Meiragtx Holdings
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
3.63% Insiders
18.38% Mutual Funds
25.07% Other Institutional Investors
40.16% Public Companies and
Individual Investors